According to the latest CPIC issued CYP2C19-clopidogrel recommendations [20], patients with intermediate CYP2C19 activity should avoid clopidogrel if they are using it for acute coronary syndrome (ACS) or following a percutaneous cardiac intervention (PCI). This evidence concerns the gene CYP2C19 and acute coronary syndrome.